Solid Biosciences Inc. (SLDB) earnings
SLDB earnings moved a median of -2.32% by the close. Quarterly and annual SLDB reports and results, each read against the price at its own news timestamp. Back to the SLDB overview →
20 measured SLDB earnings events.
Where these SLDB earnings landedvs 20 measured SLDB earnings reactions
| Middle 50% of SLDB earnings reactions | -5.10% to +5.08% |
|---|---|
| Median reaction (to close) | -2.32% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 SLDB earnings events with a measured close landed between -5.10% and +5.08%; 30% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Solid Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.65% | -1.64% | |
| Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | +0.65% | -1.64% | |
| Form 10-Q Solid Biosciences Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.33% | -1.60% | |
| Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | +1.33% | -1.60% | |
| Form 10-K Solid Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | -0.41% | -5.00% | |
| Form 10-Q Solid Biosciences Inc. For: Sep 30 | SEC filing · Form 10-Q | -5.10% | -6.48% | |
| Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions | Press release | -5.10% | -6.48% | |
| Form 10-Q Solid Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.93% | +10.60% | |
| Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | +0.93% | +10.60% | |
| Form 10-Q Solid Biosciences Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.54% | -4.15% | |
| Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -5.54% | -4.15% | |
| Form 10-K Solid Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | +4.19% | +3.24% | |
| Form 10-Q Solid Biosciences Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.64% | -5.41% | |
| Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | -1.64% | -5.41% | |
| Form 10-Q Solid Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.95% | +10.60% | |
| Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | +2.95% | +10.60% | |
| Form 10-Q Solid Biosciences Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.95% | -3.00% | |
| Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results | Press release | +1.95% | -3.00% | |
| Form 10-K Solid Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | +0.09% | +14.51% | |
| Form 10-Q Solid Biosciences Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -22.55% |
Keep exploring
More SLDB: analyst actions → · SEC filings → · SLDB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Halozyme Therapeutics, Inc. (HALO) | 374 | -0.11% | 48% |
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.